JPWO2020232190A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020232190A5 JPWO2020232190A5 JP2021568650A JP2021568650A JPWO2020232190A5 JP WO2020232190 A5 JPWO2020232190 A5 JP WO2020232190A5 JP 2021568650 A JP2021568650 A JP 2021568650A JP 2021568650 A JP2021568650 A JP 2021568650A JP WO2020232190 A5 JPWO2020232190 A5 JP WO2020232190A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- ripk3
- inflammatory
- condition involving
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 101001089266 Homo sapiens Receptor-interacting serine/threonine-protein kinase 3 Proteins 0.000 claims description 13
- 102100033729 Receptor-interacting serine/threonine-protein kinase 3 Human genes 0.000 claims description 13
- 108091000080 Phosphotransferase Proteins 0.000 claims description 10
- 102000020233 phosphotransferase Human genes 0.000 claims description 10
- 208000027866 inflammatory disease Diseases 0.000 claims description 8
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 230000002757 inflammatory effect Effects 0.000 claims description 7
- 241000712431 Influenza A virus Species 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 4
- -1 carrier Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 10
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 102000001253 Protein Kinase Human genes 0.000 description 3
- 108060006633 protein kinase Proteins 0.000 description 3
- 125000006414 CCl Chemical group ClC* 0.000 description 2
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 description 2
- 108010079933 Receptor-Interacting Protein Serine-Threonine Kinase 2 Proteins 0.000 description 2
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 description 2
- 102100022502 Receptor-interacting serine/threonine-protein kinase 2 Human genes 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000021597 necroptosis Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229910014033 C-OH Inorganic materials 0.000 description 1
- 229910014570 C—OH Inorganic materials 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024145040A JP2024170457A (ja) | 2019-05-16 | 2024-08-27 | タンパク質キナーゼ阻害剤ならびに疾患および状態の治療のためのその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962848719P | 2019-05-16 | 2019-05-16 | |
| US201962848648P | 2019-05-16 | 2019-05-16 | |
| US62/848,719 | 2019-05-16 | ||
| US62/848,648 | 2019-05-16 | ||
| PCT/US2020/032784 WO2020232190A1 (en) | 2019-05-16 | 2020-05-14 | Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024145040A Division JP2024170457A (ja) | 2019-05-16 | 2024-08-27 | タンパク質キナーゼ阻害剤ならびに疾患および状態の治療のためのその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022533182A JP2022533182A (ja) | 2022-07-21 |
| JPWO2020232190A5 true JPWO2020232190A5 (enExample) | 2023-05-02 |
| JP7546603B2 JP7546603B2 (ja) | 2024-09-06 |
Family
ID=70919255
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021568650A Active JP7546603B2 (ja) | 2019-05-16 | 2020-05-14 | タンパク質キナーゼ阻害剤ならびに疾患および状態の治療のためのその使用 |
| JP2024145040A Pending JP2024170457A (ja) | 2019-05-16 | 2024-08-27 | タンパク質キナーゼ阻害剤ならびに疾患および状態の治療のためのその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024145040A Pending JP2024170457A (ja) | 2019-05-16 | 2024-08-27 | タンパク質キナーゼ阻害剤ならびに疾患および状態の治療のためのその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220194937A1 (enExample) |
| EP (2) | EP4480485A3 (enExample) |
| JP (2) | JP7546603B2 (enExample) |
| AU (1) | AU2020275304B2 (enExample) |
| CA (1) | CA3137869A1 (enExample) |
| WO (1) | WO2020232190A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018213219A1 (en) * | 2017-05-15 | 2018-11-22 | University Of Houston System | Pyrido[2,3-d]pyrimidin-7ones and related compounds as inhibitors of protein kinases |
| AU2020275304B2 (en) * | 2019-05-16 | 2025-01-23 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions |
| CN113072471B (zh) * | 2021-03-02 | 2022-09-16 | 四川美大康华康药业有限公司 | 一种利非司特中间体及其制备方法 |
| WO2024097805A1 (en) * | 2022-11-01 | 2024-05-10 | Trustees Of Tufts College | Mixed lineage kinase domain like pseudokinase (mlkl) activators |
| WO2024199388A1 (zh) * | 2023-03-29 | 2024-10-03 | 微境生物医药科技(上海)有限公司 | 作为myt1抑制剂的化合物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL117923A (en) * | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
| KR20010023089A (ko) * | 1997-08-20 | 2001-03-26 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 단백질 티로신 키나제 및 세포주기 키나제 매개의 세포증식 억제용 나프티리디논 |
| EP1255755A1 (en) * | 2000-01-27 | 2002-11-13 | Warner-Lambert Company | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease |
| WO2014031571A1 (en) * | 2012-08-21 | 2014-02-27 | Icahn School Of Medicine At Mount Sinai | Treatment of viral infections |
| WO2015179436A1 (en) * | 2014-05-19 | 2015-11-26 | Sanford-Burnham Medical Research Institute | Inflammation therapy using mekk3 inhibitors or blocking peptides |
| WO2018213219A1 (en) | 2017-05-15 | 2018-11-22 | University Of Houston System | Pyrido[2,3-d]pyrimidin-7ones and related compounds as inhibitors of protein kinases |
| AU2020275304B2 (en) * | 2019-05-16 | 2025-01-23 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions |
-
2020
- 2020-05-14 AU AU2020275304A patent/AU2020275304B2/en active Active
- 2020-05-14 JP JP2021568650A patent/JP7546603B2/ja active Active
- 2020-05-14 CA CA3137869A patent/CA3137869A1/en active Pending
- 2020-05-14 WO PCT/US2020/032784 patent/WO2020232190A1/en not_active Ceased
- 2020-05-14 EP EP24191377.1A patent/EP4480485A3/en active Pending
- 2020-05-14 EP EP20729566.8A patent/EP3968991B1/en active Active
- 2020-05-14 US US17/595,406 patent/US20220194937A1/en active Pending
-
2024
- 2024-08-27 JP JP2024145040A patent/JP2024170457A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021240103B2 (en) | Substituted pyrrolizine compounds and uses thereof | |
| US10160743B2 (en) | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | |
| US20230212143A9 (en) | Prmt5 inhibitor compounds | |
| JP6283033B2 (ja) | ウイルス感染症およびさらなる疾患の処置のためのアシルアミノピリミジン誘導体 | |
| JP2017505779A5 (enExample) | ||
| KR20170081228A (ko) | 티족사나이드, 그의 유사체 또는 염의 전구 약물을 이용한 치료 조성물 및 방법 | |
| CA3130511A1 (en) | Inhibitors of integrated stress response pathway | |
| CN113365998A (zh) | 用于parp抑制剂的吲哚并七元酰肟类似物 | |
| CA2679198A1 (en) | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
| MX2019005706A (es) | Inhibidores de la tirosina quinasa de bruton. | |
| EP3068387A1 (en) | Compounds and methods for the treatment of malaria | |
| JP2024170457A5 (enExample) | ||
| WO2023125825A1 (en) | Anticoronviral compounds and compositions and uses thereof | |
| JP2019529460A5 (enExample) | ||
| ZA200608712B (en) | Substantially pure 2-{[2-(2-methylamino-pyrimidin-4-yl)-1II-indole-5-carbonyl]-amino}-3-(phenylpyridin-2-yl-amino)-propionic acid as an IkB kinase inhibitor | |
| JPWO2020232190A5 (enExample) | ||
| CN111601788A (zh) | 衣壳蛋白装配抑制剂、其药物组合物和用途 | |
| JP2005511535A5 (enExample) | ||
| RU2008112181A (ru) | Применение конденсированных производных имидазола для лечения заболеваний, опосредованных рецептором ccr3 | |
| MA32473B1 (fr) | Dérivés de 5-(4-méthanesulfonyl-phényl)-thiazole pour le traitement de maladies inflammatoires aiguës et chroniques | |
| JP2019509316A (ja) | ヒトライノウイルスの阻害剤としてのアルキニルヌクレオシド類似体 | |
| CN113842386A (zh) | 具有广谱抗病毒活性的药物 | |
| JP2017522383A5 (enExample) | ||
| JPWO2020252383A5 (enExample) | ||
| JPWO2020243135A5 (enExample) |